Encision(ECIA)

Focus: Encision is a public medical device company specializing in laparoscopic surgery devices, operating at modest revenue scale with flat annual sales of $7M.

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Encision

AI assessmentNot Hiring

No open roles listed right now. Follow Encision to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$7M

FY2025

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

SEC Filings: 2 available

Financials (FY2025)

Help build intelligence for Encision

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Publicly traded company provides liquidity and institutional credibility rare in device-stage companies
Focused specialty in laparoscopic surgery represents a defensible, procedural market with recurring revenue potential
Early-stage R&D intensity (9%) suggests room for product development and innovation contribution

Watch Out For

Severe financial distress: $43K cash position in FY2025 with ongoing losses ($691K net income decline) indicates existential solvency risk
Zero active job openings and flat revenue ($7M for two consecutive years) suggest minimal hiring or growth trajectory
R&D spending declining year-over-year ($816K to $622K) indicates contracting innovation investment and likely workforce constraints

Generated by Claude from Encision's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

R&D Spend

$622K(9%)24%

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo